BioArctic

BioArctic FCF Margin

The Free Cash Flow Margin of BioArctic (BIOA B.ST) as of Sep 25, 2026 is 71.07 %. In the previous year, Free Cash Flow Margin was -133.27 % — a change of -153.33% (higher).

FCF Margin

71.07 %

YoY

-153.33%

Last updated:

Free Cash Flow Margin of BioArctic is 2026 71.07 % . Free Cash Flow Margin of BioArctic was 2025 -133.27 % . It decreases by -153.33% higher compared to the previous year.

The BioArctic FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-28.62 SEK
Jan 1, 2019
114.95 SEK
Jan 1, 2020
-168.11 SEK
Jan 1, 2021
-625.78 SEK
Jan 1, 2022
-19.44 SEK
Jan 1, 2023
49.07 SEK
Jan 1, 2024
-133.27 SEK
Jan 1, 2025
71.07 SEK
The BioArctic FCF Margin history
YEARFCF MarginYoY
71.07 %-153.33%
-133.27 %-371.60%
49.07 %-352.38%
-19.44 %-96.89%
-625.78 %+272.24%
-168.11 %-246.25%
114.95 %-501.70%
-28.62 %-70.99%
-98.63 %-115.50%
636.44 %-1,513.02%
-45.04 %—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Free Cash Flow Margin of BioArctic is 71.07 % in 2026.

Free Cash Flow Margin of BioArctic changed from -133.27 % to 71.07 %, representing a -153.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin BioArctic since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

Margins — BioArctic

All Key Metrics — BioArctic